The GENEOM clinical trial (ClinicalTrials.gov Identifier: NCT00959556) involved collecting blood samples from 342 BC patients and investigating 88 SNPs of PI3 K/AKT/mTOR signaling genes (including: 17 SNPs of AKT1, 4 of AKT2, 2 of FGFR1, 7 of mTOR, 4 of PDK1, 11 of PI3 KR1, 20 of PI3 KCA, 17 of PTEN, and 6 of RPS6KB1). This evidence concerns the gene AKT1 and breast cancer.